Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
December 14, 2021– Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments…Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer
December 9, 2021NEW YORK, December 9, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference
November 23, 2021NEW YORK, November 23, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis
November 18, 2021NEW YORK, November 18, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity
November 4, 2021– Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis – – Initiated Phase 2 CALLIPER Trial…Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update
November 1, 2021– Webcast to be Held at 8:00 am ET on November 4, 2021 – NEW YORK, November 1, 2021 – Immunic,…Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis
October 28, 2021– Top-Line Data Expected in the Second Quarter of 2022 – NEW YORK, October 28, 2021 – Immunic, Inc. (Nasdaq: IMUX), a…Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935
October 27, 2021– Represents the First Time Patients Will Be Treated With the Company’s Potentially Best-In-Class RORγt Inverse Agonist – NEW YORK,…Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
October 14, 2021NEW YORK, October 14, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis
September 30, 2021NEW YORK, September 30, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
